|Bid||32.930 x 7700|
|Ask||32.940 x 9700|
|Day's Range||32.690 - 32.955|
|52 Week Range||29.830 - 37.390|
|PE Ratio (TTM)||27.70|
|Dividend & Yield||1.28 (3.87%)|
|1y Target Est||N/A|
Philosopher Blaise Pascal never faced proof he was wrong to believe in God. AstraZeneca's Pascal Soriot has discovered his faith in the Mystic cancer drug trial really was misplaced. A failure of a key ...
For the past few months, Gilead Sciences, Inc. (NASDAQ:GILD) could not fulfill the technical upside promise. Last night, GILD report earnings and the stock is spiking toward $76. Click to Enlarge Coming into the earnings, sentiment had also shifted in favor of better days to come from GILD stock, and I am one who likes to trade with the market sentiment.
Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.